The poultry industry, particularly broiler production, is vital for global food security, facing persistent challenges in the Middle East and North Africa due to respiratory diseases, notably avian influenza H9N2. This subtype causes significant economic losses and increased mortality in broilers. This review addresses the current situation and impact of H9N2 avian influenza, emphasising the crucial role of biosecurity and farm management (Part I), exploring the concept of mutual conspiracy (Part II), and discussing targeted control through vaccination (Part III), with a focus on the Newflend vaccine.
Respiratory diseases, including H9N2 avian influenza, require stringent biosecurity measures to prevent infection and spread. A continuous improvement process should address areas like viral colonisation prevention through audits. Effective farm management strategies, such as temperature control, air quality, and litter management, play a vital role in reducing infectious pressure.
Figure 1- Key points of biosecurity & management in preventing respiratory diseases.
Temperature Control: Research reveals temperature-dependent fluctuations in H9N2 pathogenicity, emphasising the importance of maintaining optimal rearing temperatures.
Air Quality: Poor air quality exacerbates respiratory infections, making birds more susceptible. Proper ventilation is crucial to obtain good oxygenation, and dynamic systems significantly reduce pathogen prevalence.
Relative Humidity and Litter Management: Maintaining appropriate humidity levels and effective litter management is crucial in controlling respiratory diseases. Well-managed litter minimises pathogen proliferation, reducing the risk of respiratory infectious diseases.
Density and Micro-Climate Impact: Poultry density influences micro-climate, affecting bird health. Managing flock density is crucial for maintaining suitable air quality, proper oxygenation, and optimal animal health.
Figure 2- Effect of rearing conditions on the outcome of H9 challenge.
The term “mutual conspiracy” describes the synergistic interaction of pathogens like H9N2 with others, amplifying the challenge of disease control. Field data supports the hypothesis that higher ambient temperatures increase vulnerability to respiratory disease outbreaks, emphasising the practical implications of managing temperature.
Figure 3 – Reproduction of the macroscopic & histological lesions of the co-infection H9 & IBV but with a stand alone H9N2 challenge (+lower ventilation and higher temperature).
The Newflend vaccine marks a milestone in H9N2 immunisation, providing an innovative approach to managing H9 and addressing mutual conspiracy complexities. Its unique concept offers a new mechanism in respiratory disease control, successfully tackling the dual challenge of H9N2 and other respiratory pathogens.
Effective biosecurity and strategic farm management are critical in protecting broilers against respiratory diseases’ mutual conspiracy. Understanding the interplay of factors like temperature, air quality, and density, along with the introduction of innovative vaccines like Newflend, is essential for sustainable broiler production, mitigating economic losses, and ensuring global food security.
References available upon request.
"*" indicates required fields
Ceva Santé Animale (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines, pharmaceutical and animal welfare products for farm and companion animals, as well as equipment and services to provide the best experience for our customers. With 6,500 employees located in 47 countries, Ceva strives daily to bring to life its vision as a OneHealth company: “Together, beyond animal health”. 2022 turnover: €1.53 billion. Use the links below to learn more about Ceva.
Ceva Santé Animale (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines, pharmaceutical and animal welfare products for farm and companion animals, as well as equipment and services to provide the best experience for our customers. With 6,500 employees located in 47 countries, Ceva strives daily to bring to life its vision as a OneHealth company: “Together, beyond animal health”. 2022 turnover: €1.53 billion. Use the links below to learn more about Ceva.
Notifications
Your Privacy Matters
It's your legal right to choose which information a website may store and have access to. With your permission, we and our third-party partners (18) store and/or access information on a device, such as unique identifiers in cookies and browsing data to collect and process personal data.
We and our partners do the following data processing:
Store and/or access information on a device, Advertising based on limited data and advertising measurement, Personalised content, content measurement, audience research, and services development
If you accept any or all of these, you will have agreed to this website's use of cookies for these purposes. You may also choose to refuse consent, but certain personalized features of the site won't be available to you.